Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Up 4.8%

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) traded up 4.8% on Tuesday . The stock traded as high as $19.00 and last traded at $18.86. 83,765 shares traded hands during trading, a decline of 79% from the average session volume of 394,420 shares. The stock had previously closed at $18.00.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Evercore ISI upped their target price on Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Wedbush reiterated an “outperform” rating and issued a $30.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, April 23rd. Wells Fargo & Company initiated coverage on Kiniksa Pharmaceuticals in a research note on Friday, May 3rd. They issued an “overweight” rating and a $34.00 price target for the company. Finally, JPMorgan Chase & Co. increased their price objective on Kiniksa Pharmaceuticals from $26.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Four research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $31.00.

Kiniksa Pharmaceuticals Stock Performance

The company has a 50 day moving average price of $19.05 and a 200 day moving average price of $19.04. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of 170.36 and a beta of 0.38.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, April 23rd. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.11). The firm had revenue of $79.90 million during the quarter, compared to analyst estimates of $76.97 million. Kiniksa Pharmaceuticals had a net margin of 2.78% and a negative return on equity of 7.26%. The business’s quarterly revenue was up 65.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.18) earnings per share. Research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.1 EPS for the current year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several large investors have recently added to or reduced their stakes in KNSA. Schonfeld Strategic Advisors LLC lifted its position in Kiniksa Pharmaceuticals by 180.1% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 208,500 shares of the company’s stock valued at $3,622,000 after acquiring an additional 134,070 shares in the last quarter. Alps Advisors Inc. lifted its position in shares of Kiniksa Pharmaceuticals by 38.3% during the 3rd quarter. Alps Advisors Inc. now owns 71,103 shares of the company’s stock worth $1,235,000 after buying an additional 19,709 shares in the last quarter. GSA Capital Partners LLP lifted its position in shares of Kiniksa Pharmaceuticals by 81.9% during the 3rd quarter. GSA Capital Partners LLP now owns 63,216 shares of the company’s stock worth $1,098,000 after buying an additional 28,468 shares in the last quarter. Tejara Capital Ltd lifted its position in shares of Kiniksa Pharmaceuticals by 3.2% during the 3rd quarter. Tejara Capital Ltd now owns 35,000 shares of the company’s stock worth $608,000 after buying an additional 1,069 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Kiniksa Pharmaceuticals during the 4th quarter worth approximately $311,000. Institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.